Physician profile
Paul S Cunningham
NPI 1093881344
$2,923.86
in general payments reported to CMS, 2019-2025
20 companies · $769 in 2025
The $769 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $187 · 2021: $478 · 2022: $372 · 2023: $276 · 2024: $534 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,578.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $446.80 | 2024-2025 | Tepezza |
| Abbvie INC. | $336.53 | 2023-2025 | Durysta |
| Alcon Vision LLC | $314.47 | 2021-2025 | Rocklatan, Clareon, Clareon Panoptix Pro |
| Aerie Pharmaceuticals, INC. | $286.73 | 2019-2021 | |
| Allergan, INC. | $251.51 | 2019-2022 | |
| Horizon Therapeutics Plc | $246.19 | 2021-2023 | Tepezza |
| Sun Pharmaceutical Industries INC. | $233.02 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $227.21 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $152.50 | 2019-2023 | |
| Kala Pharmaceuticals, INC. | $84.02 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.56 | 2019-2020 | |
| Dompe US, INC. | $47.72 | 2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $44.56 | 2021 | |
| Bausch & Lomb Americas INC. | $42.46 | 2022-2024 | Vyzulta |
| Oyster Point Pharma, INC. | $35.83 | 2022-2023 | Tyrvaya |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $32.63 | 2019 | |
| Biotissue Holdings INC. | $32.17 | 2022 | |
| Thea Pharma INC. | $22.44 | 2023 | Iyuzeh |
| Sight Sciences, INC. | $20.27 | 2021 | |
| Eyevance Pharmaceuticals LLC | $17.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Cunningham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.